

Current CF-Related Research Grant Support

Principal Investigator [MPI or Co-Investigator]	Supporting Organization/ Grant Number	Title	Project Period	Annual Direct Costs	Identify other DK Center(s), if grant is included as part of its research base
Last Name, First Name	Complete number if none, then write N/A	Complete title as shown on the grant		Direct Cost \$US	Center name, if applicable
Ahmad, Shama	NIH/R21ES030525	Airway Stem Cell Activation in the Mitigation of Halogen-Induced Lung Injury	07/01/2020 - 06/30/2023	\$ 125,000.00	
Aller, Stephen G	Cystic Fibrosis Research Institute/531342	Role of Arginine-933 in CFTR Folding, Gating and Potentiator Drug Binding	06/01/2021 - 05/31/2023	\$ 70,000.00	
Aller, Stephen G	Bright Focus Foundation/M2019212	Cryo-EM of ABCA4 and Correction in Macular Degeneration Defects *	07/01/2019 - 06/30/2022	\$ 70,000.00	
Antony, Veena B	NIH/R01ES029981	Environmental Cadmium and COPD	09/21/2018 - 06/30/2023	\$ 352,627.00	
Barnes, Stephen	VA/36C24E21P0175	Neutrophil Exosomes: New Pathogenic Entities in COPD **	09/13/2021 - 09/12/2025	\$ 60,000.00	
Bedwell, David M	CFF/002492G221	Examining the Mechanism of a Readthrough Compound that Degrades eRF1	11/01/2021 - 10/31/2023	\$ 125,000.00	
Bedwell, David M	Gilbert Family Foundation/563676	Exploring Nonsense Suppression as a Treatment for NF1	12/01/2018 - 11/30/2022	\$ 380,952.00	
Bedwell, David M	CFF/Southern Research Institute	The Identification of New Treatments for Cystic Fibrosis Caused by Premature Termination Codons-Bedwell Subcontract	08/14/2015 - 12/31/2022	\$ 250,000.00	
Birket, Susan Elizabeth	CFF/BIRKET20A0	The CF Rat as an In Vivo Model of Airway Infection	07/01/2020 - 06/30/2022	\$ 200,000.00	
Birket, Susan Elizabeth	CFF/BIRKET20GO	The Mechanisms Underlying the Muco-Inflammatory Cycle in the CF Lung	05/01/2020 - 04/30/2023	\$ 80,000.00	
Birket, Susan Elizabeth	CFF/ROWE17XX0	Mechanisms of and Therapies for Abnormal Mucus Adhesion and Clearance in CF	08/01/2020 - 07/31/2022	\$ 149,999.00	
Birket, Susan Elizabeth	Elox Pharmaceuticals	ELX-02 Nebulization Efficiency in a G542X Rat	08/10/2021 - 08/09/2023	\$ 38,486.00	
Birket, Susan Elizabeth	NIH/R01HL153079	The Role of Airway Mucus in Infection and Inflammation	06/01/2021 - 05/31/2026	\$ 272,742.00	
Birket, Susan Elizabeth	NIH/R01HL153079	The Role of Airway Mucus in Infection and Inflammation, Supplement	06/01/2021 - 05/31/2026	\$ 30,305.00	
Birket, Susan Elizabeth	NIH/University of Kansas/R01AI138970	Vaccines To Counter Emerging Antibiotic Resistance	04/01/2018 - 03/31/2023	\$ 96,554.00	
Blalock, James Edwin	NIH/R35HL135710	A Novel Exosomal Inflammatory Pathway	01/18/2017 - 12/31/2023	\$ 540,000.00	
Blalock, James Edwin	NIH/R35HL135710-06S1	A Novel Exosomal Inflammatory Pathway, Supplement	01/18/2017 - 12/31/2023	\$ 131,765.00	

Current CF-Related Research Grant Support

Principal Investigator [MPI or Co-Investigator]	Supporting Organization/ Grant Number	Title	Project Period	Annual Direct Costs	Identify other DK Center(s), if grant is included as part of its research base
Last Name, First Name	Complete number if none, then write N/A	Complete title as shown on the grant		Direct Cost \$US	Center name, if applicable
Cho, Do Yeon	CFF/CHO20A0-KB	Dysbiosis of the Sinus Microbiota in Chronic Rhinosinusitis	06/01/2020 - 05/31/2023	\$ 50,000.00	
Cho, Do Yeon	NIH/K08AI146220	Dysbiosis of the Sinus Microbiota in Chronic Rhinosinusitis	06/01/2019 - 05/31/2023	\$ 147,050.00	
Cho, Do Yeon	NIH/R21AI168894	Impact of Mucin Fermenting Microbes on The Virulence of Pseudomonas Auruginosa in Chronic Rhinosinusitis	04/22/2022 - 03/31/2023	\$ 150,000.00	
Dransfield, Mark T	NIH/K24HL140108	UAB Mentoring Program In COPD Patient Oriented Research	01/15/2018 - 12/31/2022	\$ 79,803.00	
Gaggar, Amit (Mentor)	CFF/MARGAR21F5	Role of Epidermal Growth Factor Receptor in CF Airway Neutrophils	08/01/2021 - 07/31/2023	\$ 73,468.00	
Garcia, Bryan	CHILDREN'S HOSPITAL MEDICAL CENTER (CINCINNATI)	CF Learning Network: Implementation Phase	01/01/2022 - 02/20/2023	\$ 27,200.00	
Garcia, Bryan	PARATEK PHARMACEUTICALS, LLC.	A Phase 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Omadacycline in Adult Subjects with Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc)	12/02/2021 - 12/01/2023	\$ 14,938.00	
Guimbellot, Jennifer Susan	NIH/K23HL143167	Pharmacometric Approaches to Precision Optimization of Ivacaftor Response in Cystic Fibrosis Patients	02/01/2020 - 01/31/2025	\$ 159,400.00	
Gutierrez, Hector H	ALDPH/C20115078	Cystic Fibrosis Screening of Newborn Infants	10/1/2021 – 9/30/2022	\$ 38,000.00	
Gutierrez, Hector H	CHILDREN'S HOSPITAL MEDICAL CENTER (CINCINNATI)	CF Learning Network: Implementation Phase	01/01/20 – 12/31/22	\$ 147,300.00	
Gutierrez, Hector H	CFF/000140CC321	UAB Cystic Fibrosis Center for Care, Teaching and Research	07/01/2021 - 06/30/2022	\$ 210,240.00	
Harris, William Thomas	CFF/HARRIW20G0	miR-145 Inhibition: A Novel Strategy to Improve CFTR Therapeutics	11/01/2020 - 10/31/2022	\$ 125,000.00	

Current CF-Related Research Grant Support

Principal Investigator [MPI or Co-Investigator]	Supporting Organization/ Grant Number	Title	Project Period	Annual Direct Costs	Identify other DK Center(s), if grant is included as part of its research base
Last Name, First Name	Complete number if none, then write N/A	Complete title as shown on the grant		Direct Cost \$US	Center name, if applicable
Harris, William Thomas	NIH/R01HL155119	miR-145 Target Site Blockade is a Selective Strategy to Enhance CFTR Restoration and Readthrough	09/01/2021 – 08/31/2026	\$ 250,000.00	
Harris, William Thomas	VERTEX PHARMACEUTICALS	A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Ivacaftor-responsive CFTR Mutation	12/01/2020 – 08/31/2022	\$ 14,925.00	
Harris, William Thomas	VERTEX PHARMACEUTICALS	A Phase 3, Open-Label, and Rollover Study to Evaluate The Long-term Safety and Tolerability of Lumacaftor/Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation	04/08/2020 - 04/07/2023	\$ 52,219.00	
Harrod, Kevin	American Lung Association	Novel SARS-CoV-2 Antivirals Targeting Viral Encoded Ion Channels	07/01/2021 - 06/30/2022	\$ 100,000.00	
Harrod, Kevin	NIH/R01HL149944	Influenza Regulation of Epithelial Pneumococcal Host Defense	9/10/2020 - 08/31/2024	\$ 250,000.00	
Hartman, John L.	CFF/0024621221	A Phenomic Model for N1303K-CFTR	11/01/21 - 10/31/2023	\$ 50,000.00	
Hartman, John L. (MPI-Eric Sorcher)	NIH/R01HL136414	Discovery of novel mechanisms that impact CFTR translation and contribute to cystic fibrosis pathogenesis	01/01/2021 - 12/31/2026	\$ 262,027.00	
Kappes, John C	CFF/002743221	CFTR Protein Core	01/01/2022 - 12/31/2023	\$ 250,000.00	
Kiedrowski, Megan R.	CFF/KIEDRO18F5-CI	Impact of Host Response on Antimicrobial Susceptibility in Cystic Fibrosis	03/01/2020 - 07/31/2022	\$ 110,000.00	
Kiedrowski, Megan R.	CFF/ROWE21R3	Bacterial-host Interactions in Cystic Fibrosis Chronic Respiratory Infections	7/1/2021 - 06/30/2024	\$ 200,000.00	
Krick, Stefanie	Alpha-1 Foundation	Targeting Mucociliary Clearance Pathways in Alpha 1 Antitrypsin Deficiency	07/01/2021 - 12/31/2022	\$ 75,000.00	
Krick, Stefanie	NIH/R01HL160911	Targeting Fibroblast Growth Factor Receptors in Cystic Fibrosis-Associated Airway Inflammation and Mucociliary Dysfunction	02/01/2022 - 01/31/2027	\$ 280,071.00	

Current CF-Related Research Grant Support

Principal Investigator [MPI or Co-Investigator]	Supporting Organization/ Grant Number	Title	Project Period	Annual Direct Costs	Identify other DK Center(s), if grant is included as part of its research base
Last Name, First Name	Complete number if none, then write N/A	Complete title as shown on the grant		Direct Cost \$US	Center name, if applicable
Krick, Stefanie	THE ORPHAN DISEASE CENTER/MDBR-22-105-CF	Exercise as Medicine in Cystic Fibrosis: A Pilot Study Assessing the Impact of a Telehealth Exercise Program on Adherence and Self-efficacy	02/01/2022 - 01/31/2023	\$ 106,960.00	
Krick, Stefanie	VERTEX PHARMACEUTICALS	A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation or Have at Least 1 Other Triple Combination Responsive CFTR Mutation and No F508del Mutation	12/12/2021 - 10/11/2023	\$ 18,532.00	
Krick, Stefanie	VERTEX PHARMACEUTICALS	A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF)	12/12/2021 - 10/11/2023	\$ 18,532.00	
Krick, Stefanie	VERTEX PHARMACEUTICALS	Video Telehealth Exercise Training in Cystic Fibrosis	04/06/2022 - 04/05/2024	\$ 108,013.00	
Ladores, Sigrid L	ALABAMA FRIENDS OF CYSTIC FIBROSIS	Using Hygge to Promote Wellness and Coping with Cystic Fibrosis	09/01/2021 - 08/31/2022	\$ 3,848.00	
Lal, Charitharth Vivek	NIH/K08HL141652	Mechanisms of Pulmonary Microbiota-Induced Inflammation and Vascular Dysfunction in Neonatal Lung Injury	02/03/2019 - 01/31/2024	\$ 155,200.00	
Leier, Andre	CFF/LEIER2010	Correction of CFTR mRNA Using Trans-acting Ribozymes	05/01/2020 - 01/31/2023	\$ 50,000.00	
Liu, Gang	NIH/R35HL135830	Program on Cellular Metabolism and Lung Fibrosis	01/03/2017 - 12/31/2023	\$ 450,001.00	
Liu, Rui-Ming	NIH/Tulane/P01HL114470	Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease ***	06/26/2021 - 07/31/2022	\$ 79,800.00	
Lowman, John D.	PCORI/SHEPHERD CENTER/SHEP-18-0001	Comparative Effectiveness of an Exercise Intervention Delivered via Telerehabilitation and Conventional Mode of Delivery	02/01/2022 - 01/31/2023	\$ 62,557.00	NORC

Current CF-Related Research Grant Support

Principal Investigator [MPI or Co-Investigator]	Supporting Organization/ Grant Number	Title	Project Period	Annual Direct Costs	Identify other DK Center(s), if grant is included as part of its research base
Last Name, First Name	Complete number if none, then write N/A	Complete title as shown on the grant		Direct Cost \$US	Center name, if applicable
Lowman, John D.	PCORI/SHEPHERD CENTER/SHEP-18-0002	Comparative Effectiveness of an Exercise Intervention Delivered via Telerehabilitation and Conventional Mode of Delivery	02/01/2022 - 01/31/2023	\$ 29,603.00	NORC
Matalon, Sadis	NIH/R21ES032956	Mitigation of Chlorine Injury to Mitochondria	09/04/2021 - 08/31/2023	\$ 158,564.00	
Oates, Gabriela R.	ALABAMA DEPARTMENT OF PUBLIC HEALTH/C10114065	Healthy Birmingham Metro Communities for a Tobacco-Free Future	8/13/2021 - 8/12/2022	\$ 99,700.00	
Oates, Gabriela R.	ALABAMA DEPARTMENT OF PUBLIC HEALTH/C20115097	Healthy Communities for a Tobacco-Free Future	10/01/2021 - 09/30/2022	\$ 76,000.00	
Oates, Gabriela R.	Cystic Fibrosis Foundation	Clinical Effort Against Smoke Exposure in Cystic Fibrosis (CEASE-CF)	01/01/2021 - 12/31/2022	\$ 5,000.00	
Oates, Gabriela R.	CFF/OATES20A0-1	Clinical Effort Against Smoke Exposure in Cystic Fibrosis (CEASE-CF)	01/01/2021 - 12/31/2022	\$ 80,000.00	
Patel, Rakesh Pravinchandra	NIH/R01HL153113	Role of Heme and PGP Matrikines in Lung Inflammation	09/01/2020 - 07/31/2024	\$ 368,464.00	
Poore, Thomas Spencer	CFF	Immune Profiles in CF Fungal Infection	07/09/2021 - 06/30/2023	\$ 110,416.00	
Poore, Thomas Spencer	KAUL PEDIATRIC RESEARCH INSTITUTE	Impact of Pseudomonas Aeruginosa and Aspergillus Fumigatus Co-Infection in CF	02/01/2022 - 01/31/2024	\$ 35,000.00	
Raju, S.Vamsee	NIH/R01AA027528	Acquired CFTR Dysfunction in Alcohol-related Lung Pathology	01/01/2020 - 12/31/2024	\$ 234,002.00	
Raju, S.Vamsee	SPIROVANT SCIENCES	In vivo Evaluation of Lentiviral Gene Therapy Vectors for Cystic Fibrosis	12/06/2021 - 12/05/2023	\$ 102,500.00	
Rowe, Steven M	CFF/Boston University/4500003838	The De-Novo Generation of Pulmonary Ionocytes from Human Pluripotent Stem Cells	11/01/2020 - 10/31/2022	\$ 18,000.00	
Rowe, Steven M	CFF/003384Y122	Therapeutics Development Center Award	04/01/2022 - 03/31/2023	\$ 268,242.00	
Rowe, Steven M	CFF/ROWE17XX1	Core Center for Measurements of Mucus and Mucociliary Clearance	08/01/2020 - 07/31/2022	\$ 200,000.00	
Rowe, Steven M	NIH/R35HL135816	Translational Program in CFTR-Related Airway Diseases	01/15/2017 - 12/31/2023	\$ 616,659.00	

Current CF-Related Research Grant Support

Principal Investigator [MPI or Co-Investigator]	Supporting Organization/ Grant Number	Title	Project Period	Annual Direct Costs	Identify other DK Center(s), if grant is included as part of its research base
Last Name, First Name	Complete number if none, then write N/A	Complete title as shown on the grant		Direct Cost \$US	Center name, if applicable
Rowe, Steven M	NIH/U01HL152978	Therapeutic Targeting of MUC5B in a Novel Ferret Model of Idiopathic Pulmonary Fibrosis	12/15/2020 - 11/30/2024	\$ 396,735.00	
Rowe, Steven M	NIH/S10OD030465	UAB U-SPECT6CTUHROI Imager	09/01/2021 - 08/31/2022	\$ 750,000.00	
Rowe, Steven M	CFF/SOUTHERN RESEARCH INSTITUTE	The Identification of New Treatments for Cystic Fibrosis Caused by Premature Termination Codons	08/14/2015 - 12/31/2022	\$ 250,000.00	
Scofield, Jessica	NIH/R35GM142748	Elucidating the Role of Reactive Nitrogen Species in Commensal and Pathogenic Bacterial Interactions	08/09/2021 - 06/30/2026	\$ 255,062.00	
Solomon, George Martin	ASTRAZENECA PHARMACEUTICALS	A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 52-Week, Phase III Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients With Non-Cystic Fibrosis Bronchiectasis (MAHALE)	01/31/2022 - 01/30/2027	\$ 42,512.00	
Solomon, George Martin	CFF/002536121	An Open-label Trial to Evaluate the Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and an N1303K Mutation Who are Not Currently Eligible for an FDA-Approved Modulator	10/01/2021 - 09/30/2023	\$ 495,676.00	
Solomon, George Martin	CFF/CC032-AD	UAB Cystic Fibrosis Center For Care Teaching And Research (Adult)	07/01/2017 - 06/30/2022	\$ 173,635.00	
Solomon, George Martin	CFF/SOLOMO20Y2-SVC	Potential Difference Measures Core for Advancing CFTR Therapeutics	04/01/2020 - 03/31/2024	\$ 150,000.00	
Solomon, George Martin	ELECTROMED	Clinical Effectiveness Of High Frequency Chest Wall Oscillation (HFCWO) In A Bronchiectasis Population	02/17/2022 - 02/16/2023	\$ 39,106.00	
Solomon, George Martin	INSMED PHARMACEUTICALS	"ASPEN – A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis"	12/21/2020 - 12/20/2022	\$ 7,250.00	

Current CF-Related Research Grant Support

Principal Investigator [MPI or Co-Investigator]	Supporting Organization/ Grant Number	Title	Project Period	Annual Direct Costs	Identify other DK Center(s), if grant is included as part of its research base
Last Name, First Name	Complete number if none, then write N/A	Complete title as shown on the grant		Direct Cost \$US	Center name, if applicable
Solomon, George Martin	INSMED PHARMACEUTICALS	"ASPEN – A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis"	12/21/2020 - 12/20/2022	\$ 29,000.00	
Solomon, George Martin	NIH/K08HL138153	Functional Categorization of Ciliary Motion in PCD	01/07/2019 - 12/31/2023	\$ 148,039.00	
Stalvey, Michael S.	LUMOS PHARMA	A Multicenter, 6-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2b Study of Daily Oral LUM-201 in Naive-to-Treatment, Prepubertal Children with Growth Hormone Deficiency (GHD)	05/14/2021 - 05/13/2023	\$ 77,046.00	NORC
Stalvey, Michael S.	LUMOS PHARMA	A Multicenter, 6-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2b Study of Daily Oral LUM-201 in Naive-to-Treatment, Prepubertal Children with Growth Hormone Deficiency (GHD)	05/14/2021 - 05/13/2023	\$ 49,967.00	NORC
Stalvey, Michael S.	NOVO NORDISK PHARMACEUTICALS	A Trial Comparing The Effect and Safety of Once Weekly Dosing of Somapacitan with Daily Norditropin in Children with Growth Hormone Deficiency	10/31/2019 - 10/30/2023	\$ 24,099.00	NORC
Troxler, Robert Bradley	HRSA/T72MC00001	UAB Pediatric Pulmonary Center	07/01/2020 - 06/30/2025	\$ 318,907.00	
Virella-Lowell, Isabel	CFF/UNC-Chapel Hill/5115266	Assessing Effectiveness of CF Infection Prevention & Control Guidelines	09/01/2019 - 08/31/2022	\$ 11,691.00	
Woodworth, Bradford A.	CFF/002481G221	Mechanisms and Targeted Therapies for Abnormal Mucus in Cystic Fibrosis Chronic Rhinosinusitis	11/01/2021 - 10/31/2022	\$ 125,000.00	
Worthey, Elizabeth A	CFF/WORTHE19A0	Finding and Integrating Pharma and Nutrition Linked Genomic Variation in CF	11/01/2019 - 10/31/2022	\$ 364,392.00	NORC

* Structural info cross talks with CFTR given protein structural similarities

** Exosomes also being studied in CF

*** Lung fibrotic pathways may overlap with CF; using HBE core

Table A.2: Other Current Cystic Fibrosis-Related Grant Support

Principal Investigator [MPI or Co-Investigator]	Supporting Organization/ Grant Number	Title	Project Period	Annual Direct Costs	Identify other DK Center(s), if grant is included as part of its research base
Last Name, First Name	Complete number if none, then write N/A	Complete title as shown on the grant		Direct Cost \$US	DK Center name, if applicable
Antony, Veena B	NIH/P42ES027723	Impact of Airborne Heavy Metals on Lung Diseases & the Environment - Administrative and Research Translation Core A	03/15/2020 - 01/13/2025	\$ 63,470.00	
Antony, Veena B	NIH/P42ES027724	Impact of Airborne Heavy Metals on Lung Diseases & the Environment - Heavy Metal Induced Airway Remodeling and COPD Project 1	03/15/2020 - 01/13/2025	\$ 184,614.00	
Bedwell, David M	NIH/P30DK072482	UAB CF Research and Translation Core Center - Core B	07/01/2018 - 04/30/2023	\$ 226,450.00	
Gaggar, Amit	NIH/T32HL105346	Training Program in Lung Biology and Translational Medicine	07/01/2021 - 06/30/2026	\$ 469,188.00	
Patel, Rakesh Pravinchandra	NIH/T32GM135028	UAB Predoctoral Training Grant in Translational and Molecular Sciences	07/01/2021 - 06/30/2026	\$ 155,732.00	
Rowe, Steven M	CFF/ROWE19R0	UAB Research and Development Program	07/01/2019 - 06/30/2024	\$ 550,000.00	
Rowe, Steven M	NIH/P30DK072482-13S1	UAB CF Research and Translation Core Center - A Multicenter Randomized, Double-blind, Phase 2, Placebo Controlled Study to Determine the Safety and Efficacy of Ivacaftor (VX-770) for the Treatment of Chronic Obstructive Pulmonary Disease (The Multicenter Topic Trial).	09/01/2019 - 02/28/2023	\$ 699,832.00	
Rowe, Steven M	NIH/P30DK072482	UAB CF Research and Translation Core Center - P&F Core	07/01/2018 - 04/30/2023	\$ 150,000.00	
Rowe, Steven M	NIH/P30DK072482	UAB CF Research and Translation Core Center - Core C	07/01/2018 - 04/30/2023	\$ 109,883.00	NORC
Rowe, Steven M	NIH/P30DK072482	UAB CF Research and Translation Core Center - Admin Core	07/01/2018 - 04/30/2023	\$ 80,740.00	
Scofield, Jessica (Mentor)	NIH/F31HL162487	Interactions Between Pseudomonas Aeruginosa and Streptococcus Salivarius and Effects on the Host Immune Response	02/01/2022 - 01/31/2024	\$ 37,326.00	
Swords, William E.	NIH/T32HL134640	UAB Predoctoral Training Program in Lung Diseases	07/01/2017 - 06/30/2022	\$ 159,333.00	
Woodworth, Bradford A.	NIH/P30DK072482	UAB CF Research and Translation Core Center - Core A	07/01/2018 - 04/30/2023	\$ 182,927.00	

Table A.2: Other Current Cystic Fibrosis-Related Grant Support

Principal Investigator [MPI or Co-Investigator]	Supporting Organization/ Grant Number	Title	Project Period	Annual Direct Costs	Identify other DK Center(s), if grant is included as part of its research base
Last Name, First Name	Complete number if none, then write N/A	Complete title as shown on the grant		Direct Cost \$US	DK Center name, if applicable
Worthey, Elizabeth A	NIH/U54OD030167	UAB Pilot Center for Precision Animal Modeling (C-PAM) - Bioinformatics Section	09/10/2020 - 08/31/2025	\$ 265,776.00	

Table A.3: Pending Cystic Fibrosis-Related Grant Support

Principal Investigator [MPI or Co-Investigator]	Supporting Organization/ Grant Number	Title	Project Period	Annual Direct Costs	Identify other DK Center(s), if grant is included as part of its research base
Last Name, First Name	Complete number if none, then write N/A	Complete title as shown on the grant		Direct Cost \$US	Center name, if applicable
Barnes, Stephen	NIH	Enhanced Metabolomics/Lipidomics with a SCIEX ZenoTOF 7600	02/01/2023 - 01/31/2024	\$ 600,000.00	
Bedwell, David	Cystic Fibrosis Foundation	Assay to Discover Compounds that Block eRF1/eRF3 Binding	11/01/2022 - 10/31/2024	\$ 150,000.00	
Birket, Susan Elizabeth	NIH/University of Kansas	A Prophylactic Vaccine to Prevent colonization by <i>Pseudomonas Aeruginosa</i>	09/01/2022 - 08/31/2027	\$ 100,000.00	
Birket, Susan Elizabeth	NIH/F31 AI174790 (Mentor)	Mechanisms Driving Small Colony Phenotypes of Staphylococcus Aureus in the Lung	12/01/2022 - 11/30/2024	\$ 44,248.00	
Birket, Susan Elizabeth	CFF/Massachusetts General Hospital	Development of Dynamic μ OCT (d μ OCT) for Pulmonary Cell Phenotyping in Relation to Treatment Assessment	11/01/2022 - 10/31/2024	\$ 14,800.00	
Birket, Susan Elizabeth	CFF	Bacterial Interactions During Chronic Infection in the CF Rat Lung	11/01/2022 - 10/31/2024	\$ 150,000.00	
Birket, Susan Elizabeth	CFF/UNC-Chapel Hill	Correlating in Vitro and in Vivo Antibacterial and Mucolytic Activities of Small Molecule Versus Macromolecular Nitric Oxide Donors	09/01/2022 - 08/31/2024	\$ 67,500.00	
Birket, Susan Elizabeth	CFF	CF Summer Research Program at the University of Alabama at Birmingham, Cystic Fibrosis Research Center	09/01/2022 - 08/31/2024	\$ 100,000.00	
Birket, Susan Elizabeth	NIH	Chronic Polymicrobial Infections in the Cystic Fibrosis Rat	04/01/2023 - 03/31/2028	\$ 357,337.00	
Birket, Susan Elizabeth	CFF	UAB Research and Development Program	07/01/2022 - 06/30/2024	\$ 550,000.00	
Birket, Susan Elizabeth	Emily's Entourage/University of Missouri	A Vaccine to Prevent Pseudomonas Aeruginosa and Methicillin-resistant Staphylococcus Aureus	01/01/2023 - 12/31/2024	\$ 50,000.00	
Blalock, James Edwin	NIH/R35HL166433	Pathogenic Exosomes in COPD	01/01/2023 - 12/31/2029	\$ 816,667.00	
Bray, Leigh Ann	CFF	Bray- Therapeutics Development Network (TDN) Sexual Health, Reproduction and Gender Research (SHARING) Men's Health Working Subgroup 2022	07/01/2022 - 06/30/2025	\$ 5,408.00	
Dransfield, Mark T.	American Lung Association	Airways Clinical Research Centers (ALA-ACRC) Network	07/01/2022 - 06/30/2023	\$ 67,723.00	

Table A.3: Pending Cystic Fibrosis-Related Grant Support

Principal Investigator [MPI or Co-Investigator]	Supporting Organization/ Grant Number	Title	Project Period	Annual Direct Costs	Identify other DK Center(s), if grant is included as part of its research base
Last Name, First Name	Complete number if none, then write N/A	Complete title as shown on the grant		Direct Cost \$US	Center name, if applicable
Gaggar, Amit	NIH	OTA-21-015E: Origins of Post-Acute Sequelae SARS-COV2 Infection (PASC) Lung Fibrosis		\$ 249,982.00	
Gaggar, Amit	NIH	A Novel Proteolytic System of Pulmonary Inflammation	09/01/2022 - 08/31/2027	\$ 250,000.00	
Garcia, Bryan	CFF/University of Virginia	Maximizing Home Spirometry Use in Telehealth Cystic Fibrosis Care: a multicenter QI project	01/01/2023 - 12/31/2024	\$ 34,188.00	
Guimbellot, Jennifer Susan	CFF/University of Washington	Elexacaftor/Tezacaftor/Ivacaftor after Lung Transplant	07/01/2022 - 06/30/2025	\$ 91,848.00	
Guimbellot, Jennifer Susan	CFF	Maternal and Neonatal Pharmacokinetics of CFTR Modulators - Clinical Research Program	11/01/2022 - 10/31/2025	\$ 43,845.00	
Guimbellot, Jennifer Susan	CFF	StatNet-University of Alabama at Birmingham	09/01/2022 - 08/31/2025	\$ 47,621.00	
Gutierrez, Hector H.	CFF	IMTI: International Mentoring Training Initiative	06/01/2022 - 05/31/2023	\$ 155,002.00	
Hartman, John L	NIH/R01AG076684	A Phenomic Model for Cell Quiescence		\$ 586,971.00	
Kiedrowski, Megan R.	CFF	Diagnosis of Bacterial Infections in Cystic Fibrosis by Noninvasive Imaging	11/01/2022 - 10/31/2024	\$ 55,000.00	
Krick, Stefanie	NIH	The Impact of Phosphate on Lung Inflammation and Fibrosis	02/01/2023 - 01/31/2024	\$ 285,315.00	
Krick, Stefanie	CFF	Award for Physical Therapist		\$ 31,300.00	
Krick, Stefanie	Vertex Pharmaceuticals	A Phase 3, Open-label Study Evaluating the Longterm Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis		\$ 8,221.00	
Ladores, Sigrid	CFF	Therapeutics Development Network (TDN) Sexual Health, Reproduction and Gender Research (SHARING) Men's Health Working Subgroup 2022	07/01/2022 - 06/30/2025	\$ 20,493.00	
Lal, Charitharth Vivek	NIH/R01HL166940	Microbiome and MicroRNA Based Targeted Therapeutics and Biomarker Development for Bronchopulmonary Dysplasia	09/01/2022 - 08/31/2027	\$ 447,628.00	
Liu, Gang	NIH/R01AI170913	Mechanism and Targeting of Inflammasome Activation in Lung Inflammation and Injury	10/01/2022 - 09/30/2027	\$ 353,878.00	
Liu, Gang	NIH/R35HL166567	Metabolic Mechanism and Targeting in Lung Fibrosis *	01/01/2023 - 12/31/2029	\$ 816,667.00	

Table A.3: Pending Cystic Fibrosis-Related Grant Support

Principal Investigator [MPI or Co-Investigator]	Supporting Organization/ Grant Number	Title	Project Period	Annual Direct Costs	Identify other DK Center(s), if grant is included as part of its research base
Last Name, First Name	Complete number if none, then write N/A	Complete title as shown on the grant		Direct Cost \$US	Center name, if applicable
Liu, Gang	DOD	Targeting Alveolar Epithelial Senescence in Pulmonary Fibrosis **	01/01/2023 - 12/31/2026	\$ 399,810.00	
Liu, Gang	NIH	Mechanisms of Alveolar Epithelial Senescence in Lung Fibrosis	07/01/2023 - 06/30/2028	\$ 386,418.00	
Marquez-Lago, Tatiana	CFF	Evaluation of Lung Microbiota Functional Networks in Cystic Fibrosis Patients Using Single, Triple and No CFTR Modulators		\$ 70,000.00	
Oates, Gabriela R.	CFF	Integrating Data for Engaged CF Care (IDEA)		\$ 350,000.00	
Poore, Thomas Spencer	CFF	The Intersection Between Atopy and Aspergillus Infection in Cystic Fibrosis	07/01/2022 - 06/30/2028	\$ 64,728.00	
Rowe, Steven Mark	Hospital for Sick Kids	Testing SickKids CFTR Potentiators in G551D Ferrets		\$ 18,519.00	
Solomon, George M.	CFF/University of Pittsburgh	Health Outcomes of Parents with Cystic Fibrosis (HOPE:CF)		\$ 42,512.00	
Solomon, George M.	BIOMX	A Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Nebulized Bacteriophage, Treatment in Outpatient Adult Cystic Fibrosis (CF) Subjects with Chronic Pseudomonas aeruginosa (PsA) Pulmonary Infection		\$ 21,403.00	
Solomon, George M.	CFF	Lower Airway Potential Difference Measurements with Integrated Endobronchial Catheter in Subjects with and without Cystic Fibrosis		\$ 499,971.00	
Solomon, George M.	4D Molecular Therapeutics	An Open-label, Phase 1/2 Trial of Gene Therapy 4D-710 in Adults with Cystic Fibrosis	11/16/2021 - 11/15/2022	\$ 14,790.00	
Solomon, George M.	NIH/University of Pittsburgh	Health Outcomes of Parents with Cystic Fibrosis (HOPE:CF)	09/01/2022 - 08/31/2027	\$ 9,947.00	
Solomon, George M.	INSMED PHARMACEUTICALS	"ASPEN – A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis"		\$ 38,176.00	

Table A.3: Pending Cystic Fibrosis-Related Grant Support

Principal Investigator [MPI or Co-Investigator]	Supporting Organization/ Grant Number	Title	Project Period	Annual Direct Costs	Identify other DK Center(s), if grant is included as part of its research base
Last Name, First Name	Complete number if none, then write N/A	Complete title as shown on the grant		Direct Cost \$US	Center name, if applicable
Solomon, George M.	CFF	Therapeutics Development Center Award		\$ 268,242.00	
Solomon, George M.	CFF/University of Virginia	CF Learning Network Telehealth and FIES Innovation Labs: Descriptive Analyses		\$ 9,222.00	
Solomon, George M.	CFF	Clinical Investigation of CFTR Modulators for Rare CFTR Mutations	11/01/2022 - 10/31/2025	\$ 38,890.00	
Solomon, George M.	Renovion	A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate The Safety, Efficacy, and Pharmacology of ARINA-1 Administered Twice Daily by Nebulizer in Adult Participants with Non-Cystic Fibrosis Bronchiectasis (NCFBE) with Excess Mucus and Cough.		\$ 9,522.00	
Stalvey, Michael S.	CFF/University of Pittsburgh	Men's Sexual and Reproductive Health in Cystic Fibrosis		\$ 77,823.00	
Swords, William E.	CFF	Microbial Interactions in Cystic Fibrosis		\$ 150,000.00	
Swords, William E.	CFF	Achromobacter Xylosoxidans as a CF related Opportunist		\$ 50,000.00	
Swords, William E.	NIH/R01HL166497	Microbial Interactions in Cystic Fibrosis	12/01/2022 - 11/30/2027	\$ 247,214.00	
Swords, William E.	NIH/	Pathogenesis of Stenotrophomonas maltophilia Respiratory Infections	04/01/2023 - 03/31/2028	\$ 250,000.00	
Swords, William E.	NIH/	Pathogenesis of Achromobacter Xylosoxidans Infections	04/01/2023 - 03/31/2025	\$ 137,500.00	
Woodworth, Bradford A.	NIH/R21AT012234	A Ginsenoside TMEM16A Potentiator for Cystic Fibrosis	09/01/2022 - 08/31/2024	\$ 275,000.00	
Woodworth, Bradford A.	NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH	Investigation into the Mechanism of Action of CFTR Potentiator, Icenticaftor in Sinonasal Epithelium		\$ 55,535.00	

* mRNA therapeutics

** Lung sensece pathways may overlap with CF